Information  X 
Enter a valid email address

Synairgen positive on asthma study latest

By BFN News | 08:53 AM | Tuesday 28 June, 2011


Synairgen plc, the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, has provided an update on its Phase II asthma study. The company has announced that the outcome of the review does not require it to alter the total number of subjects required to be dosed in the study, which remains at 140. The recent fundraising has allowed Synairgen to take steps to accelerate recruitment through the addition of 10 new sites, so that it can dose the last subjects during this autumn's rhinovirus season. The interim review also included a review of blinded safety related data and this data suggested that the drug remains well tolerated. At 24 June 2011, 197 subjects had been recruited into the pre-treatment pool and, of these, 74 had been dosed. The results of the trial are expected early in Q1 (calendar) 2012. Richard Marsden, Chief Executive, commented: "We are delighted that the asthma study is progressing well. As a result of the recent fundraising we have been able to accelerate the recruitment of this study, which we expect to complete prior to the end of this autumn's rhinovirus season when we anticipate at least 40% of the subjects in the pre-treatment pool will develop colds or flu symptoms." According to Synairgen, the preclinical influenza programme is progressing well, with preliminary results of efficacy against H1N1 'swine' flu expected around the end of Q3 (calendar) this year. At 8:53am: (LON:SNG) Synairgen share price was +0.5p at 25p Story provided by StockMarketWire.com

a d v e r t i s e m e n t